Predictive value of serum inflammatory markers in immunotherapy of non-small cell lung cancer
10.3760/cma.j.cn371439-20211115-00030
- VernacularTitle:血清炎性标志物对非小细胞肺癌免疫治疗的预测价值
- Author:
Hong LUO
1
;
Hong YIN
;
Guangyue HU
;
Hong TAO
Author Information
1. 苏州大学附属第一医院肿瘤科,苏州 215000
- Keywords:
Carcinoma, non-small-cell lung;
Immunotherapy;
Inflammatory markers
- From:
Journal of International Oncology
2022;49(3):177-180
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) can not only prolong the survival time of patients with non-small cell lung cancer (NSCLC) in a short time, but also achieve a lasting response to the tumor. However, there has been significant heterogeneity in the efficacy of ICIs among patients with different types of NSCLC, and there has been still a lack of universal biomarkers to predict the benefit of ICIs treatment. Inflammation has played a definite role in the occurrence and development of tumors, and a variety of inflammatory markers in serum also have become clinical indicators reflecting immune status, such as lactate dehydrogenase, C-reactive protein, serum neutrophils, lymphocytes, platelets and other indicators. These inflammatory markers are easy to obtain and are associated with the prognosis of a variety of solid tumors.